A pharmacokinetic study of prednimustine as compared with prednisolone plus chlorambucil in cancer patients.
The pharmacokinetic characteristics of prednisolone and of chlorambucil and its beta-oxidized metabolite, phenylacetic mustard (PAM) were studied in plasma after the oral administration of 200 mg prednimustine (Sterecyt) and a regimen consisting of 20 mg prednisolone plus 20 mg chlorambucil, respectively. A total of 12 cancer patients completed this trial. The drugs were given in a cross-over study as single doses, and serial plasma samples were collected for 32 h. Chlorambucil and PAM were assayed by a gas chromatographic/mass spectrometry method and prednisolone, by radioimmunoassay. The median relative availability of the prednisolone and chlorambucil moiety in prednimustine was 19% and 16%, respectively. Prednisolone, as well as chlorambucil and PAM, appeared later and at a significantly lower concentration in plasma after treatment with prednimustine as compared with the mixture of chlorambucil and prednisolone. We also found that the elimination phase of chlorambucil and PAM in plasma is prolonged after the administration of prednimustine as compared with chlorambucil per se. In contrast, the elimination of the prednisolone moiety of prednimustine and that following the administration of a plain prednisolone tablet did not seem to differ. The modified plasma profile of the alkylating components following prednimustine administration may be important for the clinical efficacy of prednimustine.
Bastholt
L
L
Dept. of Oncology, Odense University Hospital, Denmark.
Johansson
C J
CJ
Pfeiffer
P
P
Svensson
L
L
Johansson
S A
SA
Gunnarsson
P O
PO
Mouridsen
H
H
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use; D001682:Biological Availability; D002699:Chlorambucil / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics; D005260:Female; D008401:Gas Chromatography-Mass Spectrometry; D006801:Humans; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000097:blood* / Q000188:drug therapy; D011238:Prednimustine / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D011239:Prednisolone / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics; D011863:Radioimmunoassay; D013997:Time Factors
D002699:Chlorambucil; D011238:Prednimustine; D011239:Prednisolone